RxDoctor Payments Data

Nichole Rioux

Optometrist · Helena, MTNPI 1730315730

Payments from drug & device makers

What this record shows

This record is dominated by other: $980 of the $1,460 with a category attached, or 67.1%. Carl Zeiss Meditec USA, Inc. accounts for 67.1% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2023 at $980 and has fallen 92.1% since, to $77 in 2025.

$1,460in general payments, 2019–2025

Across 13 payments — averaging $112.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Carl Zeiss Meditec USA, Inc.$980
  • Astellas Pharma US Inc$216
  • AbbVie$174
  • Carl Zeiss Meditec AG$39
  • Bausch & Lomb Americas Inc.$20
  • Optos, Inc.$18
  • plus $14 from 1 others

What the payments were for

  • Food & beverage$42429%
  • Gifts$393%
  • Entertainment$181%
  • Other$98067%

General payments by program year

19
20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,460 in reported general payments places this provider in the 85th percentile of 184 optometrist providers in Montana.

See all optometrist providers in Montana

Medicare billing

Part B allowed, 2024
$93,500
Medicare patients
548
Services billed
1,065

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine30$33,360
LumiganBimatoprost35$25,357
CombiganBrimonidine Tartrate/Timolol18$8,183
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol14$4,405
Latanoprost204$3,034
Brimonidine Tartrate17$2,852
Travoprost13$2,307
Timolol Maleate32$1,792
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat34$560
Ciprofloxacin Hcl19$307

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan$174$66,90083 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 184 optometrist providers in Montana.

Other optometrist in Helena

See the full list for Montana

Where these figures come from

Is this you, or does something look wrong? →